<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="85748">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02005250</url>
  </required_header>
  <id_info>
    <org_study_id>Thyroid Xtreme</org_study_id>
    <nct_id>NCT02005250</nct_id>
  </id_info>
  <brief_title>Bone Structure and Strength Evaluated by Extreme-CT Scan Before and After Treatment of Hyper- and Hypothyroidism</brief_title>
  <official_title>Bone Structure and Strength Evaluated by Extreme-CT Scan Before and After Treatment of Hyper- and Hypothyroidism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Steen Bonnema</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Odense University Hospital</source>
  <oversight_info>
    <authority>Denmark: Danish Health and Medicines Authority</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim to evaluate the bone structure by Dexa-scan, extreme CT and bone markers before and
      one year after treatment for a thyroid functional disorder
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Anticipated">March 2016</completion_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Thyroid extreme CT</measure>
    <time_frame>one year</time_frame>
    <safety_issue>No</safety_issue>
    <description>structure of bone measured by extreme CT before and after treatment of the thyroid disorder</description>
  </primary_outcome>
  <number_of_groups>10</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Hyperthyroidism</condition>
  <condition>Hypothyroidism</condition>
  <arm_group>
    <arm_group_label>Graves' disease - premeno</arm_group_label>
    <description>30 premenopausal women with Graves' disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Graves' disease - postmeno</arm_group_label>
    <description>30 postmenopausal women with Graves' disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>toxic nodular goiter - premeno</arm_group_label>
    <description>30 premenopausal women with toxic nodular goiter</description>
  </arm_group>
  <arm_group>
    <arm_group_label>toxic nodular goiter - postmeno</arm_group_label>
    <description>30 postmenopausal women with toxic nodular goiter</description>
  </arm_group>
  <arm_group>
    <arm_group_label>subclinical hyperthyroidism - premeno</arm_group_label>
    <description>30 premenopausal women with subclinical hyperthyroidism</description>
  </arm_group>
  <arm_group>
    <arm_group_label>subclinical hyperthyroidism - postmeno</arm_group_label>
    <description>30 postmenopausal women with subclinical hyperthyroidism</description>
  </arm_group>
  <arm_group>
    <arm_group_label>hypothyroidism - premeno</arm_group_label>
    <description>30 premenopausal women with hypothyroidism</description>
  </arm_group>
  <arm_group>
    <arm_group_label>hypothyroidism - postmeno</arm_group_label>
    <description>30 postmenopausal women with hypothyroidism</description>
  </arm_group>
  <arm_group>
    <arm_group_label>subclinical hypothyroidism - premeno</arm_group_label>
    <description>30 premenopausal women with subclinical hypothyroidism</description>
  </arm_group>
  <arm_group>
    <arm_group_label>subclinical hypothyroidism - postmeno</arm_group_label>
    <description>30 postmenopausal women with subclinical hypothyroidism</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood, urine
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Women with untreated hyper- or hypothyroidism
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        informed consent, female sex, age 20-85 years, indication for treatment of the thyroid
        disorder,

        Exclusion Criteria:

        pregnancy, renal insufficiency, known osteoporosis, other disease that may affect bone
        metabolism, medication which affects bone metabolism, T-score below -3.5, thyroidea
        ophthalmopathy with indication for steroids,
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steen Bonnema, phd, DMsci</last_name>
    <role>Principal Investigator</role>
    <affiliation>Odense University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Steen Bonnema, phd, DMsc</last_name>
    <email>steen.bonnema@rsyd.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steen Bonnema</last_name>
      <phone>+4565413437</phone>
      <email>steen.bonnema@rsyd.dk</email>
    </contact>
    <investigator>
      <last_name>Steen Bonnema</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 3, 2013</lastchanged_date>
  <firstreceived_date>December 3, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Odense University Hospital</investigator_affiliation>
    <investigator_full_name>Steen Bonnema</investigator_full_name>
    <investigator_title>Consultant, phd, DMsc</investigator_title>
  </responsible_party>
  <keyword>osteoporosis</keyword>
  <keyword>hyperthyroidism</keyword>
  <keyword>hypothyroidism</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hyperthyroidism</mesh_term>
    <mesh_term>Hypothyroidism</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
